CardioSomaticsCardioSomaticsCardioСоматика2221-71852658-5707Eco-Vector4517710.26442/CS45177ArticlesСтатьиResearch ArticleModern approaches to the treatment and long-term management of arterial hypertension in clinical practice. Pharmacological and clinical characteristics of angiotensin II receptor blockers: focus on azilsartan medoxomil. Part IСовременные подходы к лечению и длительному контролю артериальной гипертониив клинической практике.Фармакологические и клинические особенности блокаторов рецепторов ангиотензина II:фокус на азилсартана медоксомил. Часть 1BubnovaM. GБубноваМарина Геннадьевна

д-р мед. наук, проф., рук. отд. реабилитации и вторичной профилактики сочетанной патологии с лаб. профилактики атеросклероза и тромбоза ФГБУ ГНИЦ ПМ

mbubnova@gnicpm.ruState Research Center for Preventive Medicine of the Ministry of Health of the Russian FederationФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава России1506201562NO2 (2015)ТОМ 6, №2 (2015)698024092020Copyright ©; 2015, Eco-VectorCopyright ©; 2015, ООО "Эко-Вектор"2015Eco-VectorООО "Эко-Вектор"https://creativecommons.org/licenses/by-nc-sa/4.0https://cardiosomatics.ru/2221-7185/article/view/45177

This article deals withthe overview of the pharmacological characteristics of one class of antihypertensive drugs - angiotensin II receptor antagonists (ARA II) and new member of this class - azilsartan medoxomil (Edarbi®).We have analyzed the antihypertensive efficacy of different ARA, as well as azilsartan medoxomil efficacyin case of monotherapy and in comparison with other ARA and angiotensin-converting enzyme inhibitorsamong different groups of patients.The article describes the pleiotropic effects of azilsartan medoxomil, discovered nowadays.

В статье представлен обзор фармакологических особенностей одного из классов антигипертензивных препаратов - блокаторов рецепторов ангиотензина II (БРА) - и одного из новых представителей этого класса - азилсартана медоксомила (Эдарби®). Проанализирована ангигипертензивная эффективность различных БРА, а также азилсартана медоксомила при монотерапии в сравнении с другими БРА и ингибиторами ангиотензинпревращающего фермента в разных группах пациентов. В статье изложены плейотропные эффекты азилсартана медоксомила, открытые к настоящему моменту.

arterial hypertensionangiotensin II receptor antagonistsazilsartan medoxomilартериальная гипертонияблокаторы рецепторов ангиотензина IIазилсартана медоксомилLawes C.M, Hoorn S.V, Rodgers A. Global burden of blood - pressure - related disease, 2001. Lancet 2008; 371 (Issue 9623): 1513-8.Falaschetti E, Chaudhury M, Mindell J et al. Continued Improvement in Hypertension Management in England: Results From the Health Survey for England 2006. Hypertension 2009; 53: 480-6.Levy D, Larson M.G, Vasan R.S et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-62.Воробьева О.Д., Денисенко М.Б., Елизаров В.В. и др. Демографический ежегодник России. Стат. сб. Росстат. M., 2013. http://www.gks.ruБойцов С.А., Баланова Ю.А., Шальнова С.А. и др. от имени участников исследования ЭССЕ-РФ. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваск. терапия и профилактика. 2014; 14 (4): 4-14.Оганов Р.Г., Тимофеева Т.Н., Колтунов И.Е. и др. Эпидемиология артериальной гипертонии в России. Результаты федерального мониторинга 2003-2010 гг. Кардиоваск. терапия и профилактика. 2011; 10 (1): 9-13.Grujic V, Dragnic N, Kvrgic S. Epidemiology of Hypertension in Serbia: Results of a National Survey. J Epidemiol 2012; 22 (3): 261-6.Dorobantu M, Darabont R.O, Badila E et al. Prevalence, Awareness, Treatment, and Control of Hypertension in Romania: Results of the SEPHAR Study. Int. J Hypertens 2010; Article ID 970694, 6 pages, doi: 10,4061/2010/970694Meng X.J, Dong G.H, Wang D et al. Prevalence, awareness, treatment, control, and risk factors associated with hypertension in urban adults from 33 communities of China: the CHPSNE study. J Hypertens 2011; 29 (Issue 7): 1303-10.Joffres M, Falaschetti E, Gillespie C. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross - sectional study. BMJ Open 2013; 3: e003423. doi: 10.1136/bmjopen-2013-003423Gu Q, Burt V.L, Dillon C.F, Yoon S. Trends in Antihypertensive Medication Use and Blood Pressure Control Among United States adults With Hypertension: The National Health and Nutrition Examination Survey, 2001 to 2010. Circulation 2012; 126: 2105-14.Campbell N, Young E.R, Drouin D et al. A Framework for Discussion on How to Improve Prevention, Management, and Control of Hypertension in Canada. Canadian J Cardiology 2014; 28 (Issue 3): 262-9.Mancia G, Ambrosioni E, Rosei E.A et al. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens 2005; 23: 1575-81.Ezzati M, Oza S, Danaei G, Murray C.J. Trends and cardiovascular mortality effects of state - level blood pressure and uncontrolled hypertension in the United States. Circulation 2008; 117: 905-14.Chow С.K, Teo K.K, Rangarajan S et al. Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High -, Middle -, and Low - Income Countries. JAMA 2013; 310 (9): 959-68.Tocci G, Rosei E.A, Ambrosioni E et al. Blood pressure control in Italy: analysis of clinical data from 2005-2011 surveys on hypertension. J Hypertens 2012; 30 (6): 1065-74.Schafer H.H, Sudano I, Theus G.R et al. Target blood pressure attainment with antihypertensive therapy in Swiss primary care. Blood Pressure 2012; 21 (4): 211-9.Chobanian A.V, Bakris G.L, Black H.R et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.James P.A, Oparil S, Carter B.L et al. 2014. Evidence-Based Guidelines for the Management of High Blood Pressure in Adulds. Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. doi: 10.1001/jama.2013.284427. Published online Dec 18, 2013.Леонова М.В., Белоусов Д.Ю., Штейнберг Л.Л. и др. Первые результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР III. Качественная клин. практика. 2010; 1: 54-60.Weber M.A, Schiffrin E.L, White W.B et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32: 3-15.Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219.Диагностика и лечение артериальной гипертонии. Клинические рекомендации. 2013.Carey R.M, Wang Z.Q, Sigary H.M. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000; 35: 155-63.Israilli Z.H. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertension 2000; 14 (Suppl. 1): S73-S86.Леонова М.В. Клиническая фармакология антагонистов рецепторов ангиотензина II. Фарматека. 2003; 12: 42-7.Mire D.E, Silfani T.N, Pugsley M.K. A Review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol 2005; 46: 585-93.Cernes R, Mashavi M, Zimlichman R. Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vasc Health Risk Manag 2011; 7: 749-59.Makani H, Bangalore S, Supariwala A et al. Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta - analysis. Eur Heart J 2014; 35: 1732-42.Xi G.L, Cheng J.W, Lu G.C. Meta - analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. Am J Hypertens 2008; 21: 546-52.Smith D.H, Cramer M.J, Neutel J.M et al. Comparison of telmisartan versus losartan: meta - analysis of titration - to - response studies. Blood Press Monit 2003; 8: 111-7.Mazzolai L, Maillard M, Rossat J et al. Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonists. Hypertension 1999; 33: 850-5.Turnbull F, Neal B, Ninomiya T et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta - analysis of randomised trials. BMJ 2008; 336: 1121-3.Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336: 801-8.Miura S, Fujino M, Hanzawa H et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem 2006; 281: 19288-95.Zaiken K, Cheng J.W. Azilsartan medoxomil: a new Angiotensin receptor blocker. Clin Ther 2011; 33 (11): 1577-89.Bakris G.L, Sica D, Weber M et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) 2011; 13 (2): 81-8.Sica D, White W, Weber M et al. Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. J Clin Hypertens (Greenwich) 2011; 13: 467-72.White W.B, Weber M.A, Sica D et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413-20.Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double - blind clinical study. Hypertens Res 2012; 35: 552-8.Bonner G, Bakris G, Sica D et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin - converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27: 479-86.Gitt А.К, Baumgart Р, Mahfoud F et al., for the EARLY Registry Group EARLY Treatment with azilsartan compared to ACE-inhibitors in antihypertensive therapy - rationale and design of the EARLY hypertension registry. BMC Cardiovasc Dis 2013; 13 (46): 2-8.Potthoff S, Gitt A, Braumgart P et al. Blood pressure reduction by monotherapy with azilsartan as compared to ace inhibitors in clinical practice in GERMANY. Results of the EARLY REGISTRY. J Hypertens 2014; 32: e370-1.White W.B, Weber M.A, Sica D et al. The effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in diabetic and prediabetic patients. Presented at: 22nd Scientific Meeting of the European Society of Hypertension. April 26-29, 2012. London, United Kingdom. Poster.Volpe M, Savoia C. New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil. Integr Blood Press Control 2012; 5: 19-25.Prasad A, Quyyumi A.A. Renin - angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004; 110: 1507-12.Negro R, Formoso G, Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest 2006; 29: 957-61.Nishimura H, Sanaka T, Tanihata Y et al. Losartan elevates the serum high - molecular weight - adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. Hypertens Res 2008; 31: 1611-18.Higashiura K, Ura N, Takada T et al. The effects of an angiotensin - converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose - fed rats. Am J Hypertens 2000; 13 (3): 290-7.Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of Olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens 2001; 19 (S1): S3-S14.Koh K.K, Quon M.J, Chung W.J, Shin E.K. Anti - inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 2006; 108 (1): 96-100.Yusuf S, Ostergren J.B, Gerstein H.C et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005; 112 (1): 48-53.Julius S, Kjeldsen S.E, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.Kusumoto K, Igata H, Ojima M et al. Antihypertensive, insulin - sensitising and renoprotective effects of a novel, potent and long - acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacol 2011; 669: 84-93.Zhao M, Li Y, Wang J et al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes Metab 2011; 13 (12): 1123-9.Iwai M, Chen R, Imura Y, Horiuchi M. TAK0536, new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007; 20 (5): 579-86.Kajiya T, Ho C, Wang J et al. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens 2011; 29: 2476-83.French C, Tarikuz Zaman A.K.M, Sobel B.E. The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques. J Cardiovasc Pharmacol 2011; 58: 143-8.Ye Y, Keyes K.T, Zhang C.F et al. Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial in - farct size. Cardiovasc Drugs Ther 2010; 24: 107-20.Kajiya T, Ho C, Wang J et al. Molecular and cellular effects of azilsartan: a new generation angiotensin II recеptor blocker. J Hypertens 2011; 29: 2476-83.Antunes de Araujo A., Varela H., Xavier de Medeiros C. АC et al. Azilsartan Reduced TNF-a and IL-1b Levels, Increased IL-10 Levels and Upregulated VEGF, FGF, KGF, and TGF-a in an Oral Mucositis Model PLoS One. 2015; 10(2): e0116799. Published online 2015, Feb 17. doi: 10.1371/journal.pone.0116799 PMCID: PMC4331549